114 results about "Insulin delivery" patented technology

A method may include obtaining blood glucose level readings over a diurnal period for each of a plurality of days and determining an estimated variability of the blood glucose levels over the diurnal period for the plurality of days. The method may also include modifying, based on the estimated variability of the blood glucose level, a target blood glucose level to a modified target blood glucose level, and delivering insulin, using an insulin pump, during the diurnal period based on the modified target blood glucose level.

In an infusion pump system that includes a pump that may have a user interface for pump programming, one or more smartphones or other remote control devices that interface with the infusion pump, and / or an automated insulin delivery algorithm, there is a potential conflict between commands such as boluses being programmed on multiple devices and / or calculated by the AID algorithm at the same time. In order to avoid low glucose levels that could result from delivering multiple boluses from these various sources when only one bolus is needed, systems and methods disclosed herein provide a bolus permissions and prioritization scheme that prioritizes boluses programmed with the infusion pump and one or more remote control devices and calculated by a closed loop delivery algorithm.

The embodiments described herein may relate to methods and systems for adjusting insulin delivery. Some methods and systems may be configured to adjust insulin delivery to personalize automated insulin delivery for a person with diabetes. Such personalization may include receiving and / or determining one or more user specific dosage parameters.

A method may include generating a first plurality of insulin delivery profiles that include a first series of insulin delivery actions spanning a first time interval, projecting a first plurality of future blood glucose values for each profile of the first plurality of profiles using up-to-date blood glucose levels, selecting one of the first plurality of profiles based upon comparing future blood glucose values for each profile and target blood glucose levels, delivering insulin for a second time interval that corresponds to a first action of the first profile, generating a second plurality of insulin delivery profiles for a third time interval, projecting a second plurality of future blood glucose values for each profile of the second plurality of profiles for the third time interval, and delivering a second dose of insulin for a fourth time interval shorter than the third time interval.

Disclosed herein are apparatuses and methods that can provide a delayed bolus calculator for use in closed loop diabetes therapy that can account for additional factors not taken into account in regular meal bolus calculations when a user wants to deliver a meal bolus a period of time after a meal was consumed. A delayed bolus calculator can enable the user to enter a period of time since the meal was consumed in addition to the number of carbohydrates consumed in a meal. This enables the system to account for the amount of increased insulin from the closed loop algorithm in response to the meal and / or the time since the meal to ensure that the risk of hypoglycemia is mitigated while still reducing hyperglycemia.

A method may include obtaining blood glucose level readings over a diurnal period for each of a plurality of days and determining an estimated variability of the blood glucose levels over the diurnal period for the plurality of days. The method may also include modifying, based on the estimated variability of the blood glucose level, a target blood glucose level to a modified target blood glucose level, and delivering insulin, using an insulin pump, during the diurnal period based on the modified target blood glucose level.

A method may include delivering insulin, using an insulin pump and a controller, over a first diurnal time period based on a baseline basal insulin rate stored in memory. The controller may receive blood glucose data to control delivery of insulin via the insulin pump in amounts variable from the baseline basal insulin rate to control blood glucose levels for a person with diabetes (PWD). The method may also include modifying the baseline basal insulin rate stored in the memory for a second diurnal time period that is at least 20 hours after the first diurnal period based on an amount of insulin actually delivered during the first diurnal time period.

Exemplary embodiments may address the problem of missing blood glucose concentration readings from a glucose monitor that transmits blood glucose concentration readings over a wireless connection due to problems with the wireless connection. In the exemplary embodiments, an automated insulin delivery (AID) device uses an estimate in place of a missing blood glucose concentration reading in determining a predicted future blood glucose concentration reading for a user. Thus, the AID device is able to operate normally in generating insulin delivery settings despite not receiving a current blood glucose concentration reading for a current cycle. There is no need to suspend delivery of insulin to the user due to the missing blood glucose concentration reading.

Exemplary embodiments may modify the cost function parameters based on current and projected mean outcomes in blood glucose level control performance. The exemplary embodiments may modify the weight coefficient R for the insulin cost so that the value of R is not fixed and is not based solely on clinical determined values. Exemplary embodiments may also adjust the cost function to address persistent low-level blood glucose level excursions for users. The exemplary embodiments may reduce the penalty of the insulin cost by the sum of the converted insulin cost of the glucose excursions above target for a period divided by a number of cycles of average insulin action time. The AID system reduces the insulin cost by the lack of insulin in previous cycles.

An automated insulin delivery system provides an insulin injection that is computed by adding (i) the recommendation of an artificial neural network trained to mimic a constrained model predictive controller dosing rule from a neural network implementing an artificial pancreas (ii) a hypoglycemia mitigation system includeds a correction (one dose computed as the correction down to 110mg / dl based on prevailing continuous glucose monitoring and once an hour at most, unless there is a triggering BPS and G>180 mg / dl), and (iii) the current basal rate (output of the Performance Assessment System, (PAS)); that amount is then saturated by the Safety Supervision System, SSM. Finally, a priming bolus from the Bolus Priming System, BPS, is added to the total if the conditions for large glycemic excursions are detected, also saturated by SSM.

The invention discloses application of low-esterification pectin in preparation of intelligent nanoparticles for oral delivery of insulin. The application comprises preparation of pectin with different esterification degrees, subcritical water treatment of pectin and preparation of pectin-based intelligent nanoparticles. According to the invention, through esterification degree regulation and control of pectin, a subcritical water treatment process and use of appropriate auxiliary materials, the embedding efficiency of insulin and the stability of nanoparticles are remarkably improved, the degradation of insulin in a gastrointestinal tract environment is reduced, and the oral bioavailability of drugs is improved.

Techniques disclosed herein related to controlling insulin delivery. In some embodiments, the techniques may involve delivering insulin via an insulin infusion device according to a closed-loop mode of delivery. The techniques may further involve determining, at a first time point, insulin delivery is to be switched from the closed-loop mode of delivery to a second mode of delivery. The techniques may further involve switching operation of the insulin infusion device to the second mode of delivery such that insulin is delivered via the insulin infusion device according to the second mode of delivery.

A diabetes management system optimizes glucoregulatory hormone delivery using a connected glucoregulatory hormone delivery system and a computing device with a processor and non-transitory memory. The system receives glucose management data (glucose, insulin delivery, heart rate, or carbohydrate consumption data) from sensors. A digital twin metabolic model is selected and initialized based on the received data. The system simulates diabetes treatment interventions to predict glucose dynamics and determines an optimized glucoregulatory hormone parameter (e.g., insulin dose or increment that minimizes hyperglycemia and hypoglycemia risk). The determined glucoregulatory hormone parameter is transmitted to the connected glucoregulatory hormone delivery system, which may include an automated insulin delivery (AID) system or a connected insulin pen system, for implementation. By integrating real-time physiological data with predictive metabolic modeling, the system enhances glucoregulatory hormone therapy, providing personalized adjustments to improve glucose control.

Some embodiments include burden-free insulin delivery systems and methods. In some embodiments, a method may include receiving previous insulin delivery data at a user device from an insulin pump; receiving estimated glucose data at the user device from a continuous glucose monitor; determining an insulin delivery amount based on the previous insulin delivery data and the estimated glucose data to bring the estimated glucose data closer to a target glucose value without using any user-specific behavioral data physically entered by a user through a user interface of the user device within a previous period of time, the previous period of time being less than six hours; and communicating the insulin delivery amount to the insulin pump.

The invention belongs to the technical field of medical biological dressings, and provides a composite dressing with oxygen release and insulin delivery functions and a preparation method thereof.The composite dressing comprises a supporting base layer, a function slow release layer and a protective film layer which are sequentially compounded from bottom to top; the supporting base layer is a medical porous polyurethane film modified by plasma; the functional sustained release layer is composed of hyaluronic acid-chitosan composite gel, oxygen release microspheres and insulin liposome; the protective film layer is a polyethylene terephthalate film of which the surface is provided with a sawtooth edge easy to tear; through an integrated three-layer patch structure, by combining the synergistic effect of PLGA microsphere controlled-release oxygen, liposome low-molecular chitosan insulin delivery and gel matrix, the skin injury microenvironment is effectively improved, inflammation is inhibited, and the healing time is shortened.

The invention belongs to the field of drug delivery, and particularly relates to a glucose and ketone body dual-response long-acting insulin delivery system as well as a preparation method and application thereof. The glucose and ketone body dual-response long-acting insulin delivery system provided by the invention comprises a drug crystal, a polymer coating wrapping the drug crystal and a phenylboronic acid based cationic polymer modified in the polymer coating. The long-acting insulin can prolong the treatment time of the glucose-responsive insulin delivery carrier, meanwhile, the glucose-responsive insulin delivery carrier has a ketone body response behavior, ketoacidosis is inhibited, and the problems that an existing glucose-responsive insulin delivery carrier is short in treatment time, a ketone body-responsive insulin delivery carrier is difficult to construct and the like are solved.

An insulin delivery system for diabetes management includes a patch-based insulin pump configured to deliver insulin to a user, a user input button disposed on the patch-based insulin pump, a processor configured to execute a hybrid closed loop algorithm that automatically controls insulin delivery based on glucose levels. The user input button is configured to receive user input comprising a sequence of button presses that communicate contextual information about user activities to the hybrid closed loop algorithm, the contextual information being distinct from direct insulin bolus delivery commands. The contextual information may include meal intake, physical activity, and sleep status communicated through different sequences of button presses. The system includes confirmation mechanisms that provide feedback and allow cancellation of inputs, enabling discrete real-time communication of personalized data to enhance diabetes management.

A diabetes management system optimizes glucoregulatory hormone delivery using a connected glucoregulatory hormone delivery system and a computing device with a processor and non-transitory memory. The system receives glucose management data (glucose, insulin delivery, heart rate, or carbohydrate consumption data) from sensors. A digital twin metabolic model is selected and initialized based on the received data. The system simulates diabetes treatment interventions to predict glucose dynamics and determines an optimized glucoregulatory hormone parameter (e.g., insulin dose or increment that minimizes hyperglycemia and hypoglycemia risk). The determined glucoregulatory hormone parameter is transmitted to the connected glucoregulatory hormone delivery system, which may include an automated insulin delivery (AID) system or a connected insulin pen system, for implementation. By integrating real-time physiological data with predictive metabolic modeling, the system enhances glucoregulatory hormone therapy, providing personalized adjustments to improve glucose control.

A simplified insulin pump allows diabetics to identify routine patterns in their daily lifestyle that provide a generally accurate typical pattern of activity and meals. An infusion regimen can be programmed into the pump that generally correlates with this typical pattern to provide a viable treatment option for a diabetic without the need for specific and precise matching of insulin to carbohydrate consumption or activity level.

Systems and methods are provided for enabling and disabling insulin pumps in a multi- pump insulin pump system. For example, multiple pumps (e.g., patch pumps) may be rotated to deliver insulin to a user. In one example, one patch pump may be worn while another patch pump is charging. Once the battery of the patch pump worn by the user is depleted, a mobile device may cause the enabled pump in operation and worn by the user to send the latest pump settings and configuration data to the mobile device which will share the information with the disabled pump. The disabled pump will then update the pump settings based on this information and the mobile device may active the pump such that is now enabled for insulin delivery. The mobile device may also facilitate pairing between the patch pumps and a CGM device as they enabled for use and disabled.

A blood glucose monitoring system having an insulin pump operational to administer insulin to the subject, sensors associated with the subject and operational to measure the blood glucose levels of a subject, and a computing device in electronic communication with the insulin pump. The computing device includes computer readable storage mediums having program code embodied therewith. The computing device includes a closed-loop insulin delivery algorithm trained to predict the blood glucose level of the subject. The algorithm includes a data-driven multi-step- ahead blood glucose predictor integrated with a linear time-varying model predictive control law. The computing device includes programming instructions for feeding the subject's blood glucose level into the algorithm, using the algorithm to predict if the blood glucose level of the subject is expected to reach a level representing hypoglycemia or hyperglycemia, and transmitting insulin administration instructions to the insulin pump based on the prediction.

The application discloses a glucose-responsive insulin delivery system and a preparation method and application thereof, and belongs to the technical field of biomaterials. The glucose-responsive insulin delivery system provided by the application comprises a delivery carrier and a bioactive component encapsulated in the carrier; the delivery carrier is a metal polyphenol network formed by a coordination reaction between epigallocatechin gallate and metal ions; and the bioactive component comprises glucose oxidase, catalase and insulin. The glucose-responsive insulin delivery system can adjust the release of insulin according to the concentration of glucose in the surrounding environment, so that the blood glucose can be maintained at a normal level.

Disclosed are techniques, devices and systems that obtain a glucose measurement history and a liquid drug delivery history. An expected drug delivery amount may be calculated based on the obtained glucose measurement history and the obtained liquid drug delivery history. A processor may calculate a plurality of respective drug delivery amounts implemented using different advisory mode algorithms. A respective advisory drug delivery amount of the plurality of respective advisory drug delivery amounts may be selected by the processor. A recommendation may be generated based on the selected respective advisory drug delivery amount.

Embodiments described herein gradually shift a basal rate pattern for a user in time when the time on an insulin pump is changed and use glucose levels from a CGM sensor to coordinate the shift in the basal pattern with the user's actual glucose response to the changing parameters to safely transition the timing of the basal pattern as quickly as possible.

The invention relates to the technical field of biomedical engineering, and particularly discloses a portable insulin administration device which comprises a noninvasive blood glucose detection module, an insulin administration module, an insulin administration module and an insulin administration module which are sequentially arranged from bottom to top, and the noninvasive blood glucose detection module is used for monitoring the blood glucose concentration of a human body based on a counter-ion electroosmosis technology; the drug loading module is used for loading drugs, and the drugs comprise insulin; the transdermal drug delivery module is connected with the drug carrying module and used for applying pulse voltage to the skin to enhance the transdermal permeation efficiency of the skin when the monitored blood glucose concentration value is larger than a preset threshold value and driving the drug in the drug carrying module to permeate into the corium layer. The equipment monitors the blood sugar concentration of a human body in real time by adopting a counter-ion electroosmosis technology, realizes transdermal delivery of insulin through an electroporation technology, combines two functions of blood sugar concentration monitoring and insulin delivery, realizes integrated closed-loop control of symptom diagnosis and treatment, and can realize the two functions in a completely non-invasive manner, so that the operation is simple and convenient. The skin of a patient is not damaged.

Rather than using a conventional static IOB profile based on population averages, exemplary embodiments may dynamically adjust an insulin on board (IOB) profile for a user of a drug delivery system to customize the IOB profile for the user based on recent glucose value history and insulin delivery. Exemplary embodiments may calculate an insulin duration of action (DIA) for the user from a customized insulin decay curve. Exemplary embodiments may generate and send a notification to the user to help reduce the user's DIA and / or to suppress an increase in the user's DIA. Exemplary embodiments may be aimed at not unduly restricting insulin delivery for the contribution of an insulin bolus to the IOB.

A method of improving insulin delivery includes detecting a dosing event of an upcoming insulin dose, identifying a next injection site to recommend to a user for the upcoming insulin dose, and transmitting a recommended injection site to a delivery device to be displayed on the delivery device. The method further includes receiving a user selection of a plurality of injection sites to include within an injection site recommendation profile, receiving a user selection of an injection cycle to utilize within the injection site recommendation profile, and generating an injection site recommendation profile.